MetaCap

Anavex Life Sciences (AVXL) vs Coherus Oncology (CHRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Coherus Oncology (CHRS) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 68.1% versus a loss of 81.9%. Over five years, AVXL leads with a -97.0% price change compared with -98.0% for CHRS. Coherus Oncology is the larger company by market cap ($57.1 million vs $54.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-81.86%CHRS-68.12%
+126%+17%-92%
Nov 21, 20251 yearNov 20, 2026
AVXL-97.08%CHRS-98.00%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus CHRS key metrics
MetricAVXLCHRS
Share price$0.5915$0.3698
Market cap$54.83M$57.15M
1-day change-11.39%-4.47%
YTD return-83.38%-73.96%
1-year return-81.86%-68.12%
5-year return-96.96%-97.99%
EPS (TTM)$-0.14$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$42.17M
Revenue growth (YoY)—+59.81%
Net income (latest FY)$-46.38M$168.02M
Gross margin—67.24%
Operating margin—-429.51%
Net margin—398.43%
52-week high$5.36$2.62
52-week low$0.59$0.3628
Distance from 52-week high-88.96%-85.86%
Analyst consensusnonestrong_buy
Avg. price target upside—+1995.73%
Average volume1.15M1.80M
Shares outstanding92.70M154.54M
Employees34144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CHRS has outperformed AVXL by 13.7 percentage points over the past year.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

AVXL vs CHRS FAQ

Which is bigger, Anavex Life Sciences or Coherus Oncology?

Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $54.83M for Anavex Life Sciences (AVXL).

Which stock has performed better over the past year, AVXL or CHRS?

CHRS returned -68.12% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.

Are Anavex Life Sciences and Coherus Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons